Close Menu

NEW YORK ─ Bremen, Germany-based Molzym, a developer of PCR-based diagnostic test kits for European markets, is planning to enter the US in a few years with an automated, multiplex sepsis test that detects a broad range of pathogens directly from patient samples within five hours.

Molzym is developing the instrument and panel in collaboration with Munich-based Fraunhofer Institute as part of a €2 million ($2.4 million) project funded by the European Union's European Regional Development Fund and the federal state of Brandenburg, Germany.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Sponsored by

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.